New drug target can break down cancer's barrier against treatment

Cancer research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature.

The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill by damaging DNA. When the researchers removed FAK from blood vessels that grew in melanoma or lung models, both chemotherapy and radiation therapies were far more effective in killing the tumours.

The researchers also studied samples taken from lymphoma patients. Those with low levels of FAK in their blood vessels were more likely to have complete remission following treatment. This suggests that developing drugs to strike out FAK in cancer blood vessels may boost cancer treatments and prevent cancer from coming back.

Dr Bernardo Tavora, lead author on the paper from the Barts Cancer Institute, said: "This work shows that sensitivity to cancer treatment is related to our own body mistakenly trying to shield the cancer from cell-killing effects caused by radiotherapy and chemotherapy.

"Although taking out FAK from blood vessels won't destroy the cancer by itself, it can remove the barrier cancer uses to protect itself from treatment."

Cells lining the blood vessels send chemical signals, called cytokines, to the tumour to help it resist DNA damage and to recover. The researchers demonstrated that this process requires FAK in order to work, and without it, these signals are never sent – making the tumour more vulnerable to DNA damaging therapy.

Dr Kat Arney, Cancer Research UK's science communications manager, said: "This exciting research may have cracked how healthy cells in the are protecting against cancer treatments. This research was only done in mice, but it gives real hope that we can boost the effectiveness of cancer medicine and sensitise cancers to the drugs we have."

More information: Tavora et al. Endothelial-FAK targeting sensitises tumours to DNA-damaging therapy. Nature 2014. DOI: 10.1038/nature13541

add to favorites email to friend print save as pdf

Related Stories

Finding the Achilles' Heel of ovarian tumor growth

Jun 19, 2014

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that ...

FAK helps tumor cells enter the bloodstream

Jan 20, 2014

Cancer cells have something that every prisoner longs for—a master key that allows them to escape. A study in The Journal of Cell Biology describes how a protein that promotes tumor growth also enables cancer ...

Cancer therapy may be too targeted

Mar 16, 2014

Researchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.